| 000 | 01741 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514052544.0 | ||
| 264 | 0 | _c20030107 | |
| 008 | 200301s 0 0 eng d | ||
| 022 | _a0007-0920 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6600660 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCameron, D A | |
| 245 | 0 | 0 |
_aBlock sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cDec 2002 |
||
| 300 |
_a1365-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aAxilla |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymph Nodes _xpathology |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAnderson, A | |
| 700 | 1 | _aToy, E | |
| 700 | 1 | _aEvans, T R J | |
| 700 | 1 | _aLe Vay, J H | |
| 700 | 1 | _aKennedy, I C S | |
| 700 | 1 | _aGrieve, R J | |
| 700 | 1 | _aPerren, T J | |
| 700 | 1 | _aJones, A | |
| 700 | 1 | _aMansi, J | |
| 700 | 1 | _aCrown, J | |
| 700 | 1 | _aLeonard, R C F | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 87 _gno. 12 _gp. 1365-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6600660 _zAvailable from publisher's website |
| 999 |
_c12260873 _d12260873 |
||